Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.The FDA has granted fast track designation to AstraZeneca's anticancer drug Zactima in order to accelerate the regulatory process of the compound for the treatment of medullary thyroid carcinoma.
Subscribe to our email newsletter
The drug also received orphan-drug designation last year for the treatment of patients with follicular, medullary, anaplastic, and locally advanced and metastatic papillary thyroid cancer. There is currently no curative modality or approved chemotherapy for advanced thyroid cancer.
The drug received the designation as it is intended to treat a life threatening condition and demonstrates the potential to address an unmet medical need.
“We are pleased to receive fast track designation for Zactima for the treatment of medullary thyroid cancer, and are committed to evaluating the potential of Zactima as a new treatment option for patients with this disease,” said Dr Peter Langmuir, senior director, medical science, AstraZeneca.